マウスでは,β-アミノプロピオニトリル誘発の胸部アオートパシーはシロスタゾールとシルデナフィルに耐性である
Samuel C Tyagi1,2,3,4, Sohei Ito1,2, Jacob C Hubbuch1,2,3,4
1Saha Cardiovascular Research Center, College of Medicine, University of Kentucky, Lexington, Kentucky, United States of America.
PloS one
|August 29, 2025
まとめ
チロスタゾールとシルデナフィルは,マウスモデルにおける胸部アオートパシーを予防しなかった. これらの薬剤は,β - アミノプロピオニトリル (BAPN) で治療されたマウスの動脈瘤形成または破裂に影響を与えませんでした.
科学分野:
- 心血管研究
- 薬理学について
- 翻訳医学
背景:
- 動脈瘤と解剖を含む胸部動脈病は,重大な血管疾患である.
- シロスタゾール (PDE3阻害剤) と シルデナフィル (PDE5阻害剤) は,腹動脈動脈瘤のモデルにおいて有望である.
- 胸部アオートパシーにおける有効性は未調査のままである.
研究 の 目的:
- チロスタゾールとシルデナフィルの効果を胸部アオートパシーのマウスモデルで調べる.
- これらのフォスフォディエステラーゼ阻害剤が病気の進行を予防または緩和できるかどうかを判断する.
主な方法:
- β-アミノプロピオニトリル (BAPN) を使用したマウスの胸部アオートパシーの誘導.
- シロスタゾールまたはシルデナフィルの投与は,食事補充によるものです.
- マススペクトロメトリーを用いて薬物の存在を確認する.
- 大動脈の破裂と動脈瘤の形成の評価
主要な成果:
- BAPNは,大動脈におけるPde3aとPde5aの遺伝子発現を向上させた.
- 薬物治療により,十分な血濃度が確認されました.
- シロスタゾールもシルデナフィルは,BAPN誘発性大動脈破裂や動脈瘤の発達を変化させなかった.
結論:
- シロスタゾールとシルデナフィルは,マウスにおけるBAPN誘発の胸部アオートパシーの発症や進行に影響を与えない.
- 胸前大動脈疾患の代替治療戦略を探るにはさらなる研究が必要である.
関連する概念動画
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:30Adrenergic Agonists: Therapeutic Uses
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...